Durata Therapeutics (NASDAQ:DRTX)

CAPS Rating: 3 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar jackspicks (< 20) Submitted: 5/24/2014 2:16:53 PM : Outperform Start Price: $16.07 DRTX Score: -2.20

drtx

Recs

0
Member Avatar tsaifool (91.29) Submitted: 2/21/2014 2:38:51 PM : Outperform Start Price: $14.02 DRTX Score: +8.86

bought rights to Dalbavancin which is a once weekly injectable, if marketed correctly, could be a nice transition drug from inpt to outpt therapy, would be also useful in an OPIC/OPAT setting, hopefully it is finally approved after 10 years in a rut

Recs

0
Member Avatar simonwmich (< 20) Submitted: 1/18/2014 5:42:02 PM : Outperform Start Price: $12.76 DRTX Score: +20.81

As we enter into the era of hospital performance based reimbursement, any drug that keeps patients from being readmitted will be very attractive to hospitals. The once/week treatment also guarantees compliance vs oral meds.

Recs

0
Member Avatar line70day (< 20) Submitted: 12/1/2013 2:30:42 PM : Outperform Start Price: $11.63 DRTX Score: +31.04

A biopharmaceutical Co. devoloping therapies to treat infectous diseases and illnesses jumped 20% after acceptance of drug Dalvance for prior review by FDA

Recs

1
Member Avatar zzlangerhans (99.78) Submitted: 6/23/2013 11:33:55 AM : Outperform Start Price: $6.84 DRTX Score: +115.04

Durata has been very weak ahead of the dalbavancin NDA and MAA submissions despite what appears to be solid phase III data and the promise of priority NDA review due to QIDP status. Is the stock weak because no one talks about Durata, since Trius is the antibiotic pump du jour? Or are hedgies and institutions avoiding the stock because of dalbavancin's troublesome provenance and data concerns that aren't being revealed to retail investors? Durata might not get a big run ahead of a dalbavancin PDUFA, but it might be good for at least a 10% bump from the lows.

Results 1 - 5 of 5

Featured Broker Partners


Advertisement